Tradename | Company | Number | Date | Products |
---|---|---|---|---|
LUTATHERA | Advanced Accelerator Applications | N-208700 RX | 2018-01-26 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
lutathera | New Drug Application | 2024-12-11 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
pancreatic neoplasms | EFO_0003860 | D010190 | C25 |
gastrointestinal neoplasms | — | D005770 | C26.9 |
neuroendocrine tumors | EFO_1001901 | D018358 | D3A.8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | — | — | — | — | 1 |
Drug common name | Lutetium dotatate lu-177 |
INN | — |
Description | Lutetium (177Lu) oxodotreotide (INN) or 177Lu DOTA-TATE, trade name Lutathera, is a chelated complex of a radioisotope of the element lutetium with DOTA-TATE, used in peptide receptor radionuclide therapy (PRRT). Specifically, it is used in the treatment of cancers which express somatostatin receptors.
|
Classification | Unknown |
Drug class | Antineoplastic agent |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3989924 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB13985 |
UNII ID | — |